Patentees take note: September 21, 2018 marks the first anniversary of the Certificate of Supplementary Protection (CSP) regime in Canada, and it also marks the end of the transitional period for securing a CSP. As a result, the effective deadline for filing a CSP application is September 21, 2018 for applications where the first relevant foreign regulatory filing (as described below) occurred between September 21, 2016 and September 21, 2017.
A CSP is only available if the new drug submission (NDS) for a medicinal ingredient or combination of medicinal ingredients is timely filed in Canada. The NDS must be filed within a prescribed period of the filing of the first application for marketing approval of the medicinal ingredient or combination in the U.S., Europe or any member country thereof, Japan, Switzerland and Australia.
The prescribed period is 24 months if the CSP application is filed no later than the first anniversary of the CSP regime (i.e., September 21, 2018); otherwise, the prescribed period is 12 months. If the timely NDS filing requirement is not met, the CSP application will be refused.
A CSP application is due within 120 days of the later of the grant of marketing authorization by Health Canada (i.e., a NOC) and patent grant. However, this deadline is effectively advanced to September 21, 2018 for those CSP applications that are based on an NDS filed within 12-24 months of the first application for marketing approval in any of the noted regions.
There are other requirements for securing a CSP, as explained here. However, it is only the timely NDS filing requirement that will change after September 21, 2018.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
-
Slam dunk! New basket of countries for PMPRB reporting remain, controversial amendments to Patented Medicines Regulations dropped
On April 14, 2022, the Minister of Health announced that the Amendments to the Patented Medicines Regulations (the “Regulations”), originally released on August 18, 2019, would come into force on July...Read More -
Competition Bureau resolves misleading performance claims case
On April 27, 2022, the Competition Bureau announced that it has reached a settlement agreement with NuvoCare Health Sciences Inc and its founder (collectively “NuvoCare”), who were found to have made ...Read More -
Supreme Court of Canada denies leave to appeal refusal of NHP licence for BOLUOKE
On May 12, 2022, the Supreme Court of Canada dismissed an application by Canada RNA Biochemical (C-RNA) for leave to appeal (Docket No. 39994) a decision of the Federal Court of Appeal relating to the...Read More